The Once-Weekly Human GLP-1 Analogue Semaglutide Provides Significant Reductions in Hba1c and Body Weight in Patients with Type 2 Diabetes, Proceedings of the 48th EASD Annual Meeting
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.